<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 的股票在週五交易前因內部人士賣出活動而出現跳空下跌。該股此前收於 43.96 美元，但開盤價為 42.91 美元。Hims
&amp; Hers Health 的股票最後交易價格為 44.71 美元，成交量為 4,937,687 股。</p>
<ul>
<li>奧澤姆比熱潮：Hims
&amp; 艾利 Lilly 引領醫療保健投資</li>
</ul>
<p>具體來説，首席執行官安德魯·杜杜姆在 8 月 18 日星期一的交易中出售了 128,127 股公司的股票。這些股票以平均價格 45.06 美元出售，總價值為 5,773,402.62 美元。出售完成後，首席執行官直接持有公司 89,521 股股票，價值 4,033,816.26 美元。此次交易使其持股比例減少了 58.87%。該出售在與證券交易委員會的法律文件中披露，相關文件可通過此鏈接獲取。</p>
<p>獲取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
<h2>分析師升級和降級</h2>
<p>HIMS 已成為多份研究報告的主題。Zacks Research 在週二的報告中將 Hims
&amp; Hers Health 的股票評級從 “強力買入” 下調至 “持有”。Needham
&amp; Company LLC 在 8 月 5 日的報告中重申了對 Hims
&amp; Hers Health 股票的 “持有” 評級。德意志銀行在 5 月 7 日的報告中重申了對 Hims
&amp; Hers Health 股票的 “持有” 評級。花旗集團在 6 月 23 日的報告中重申了對 Hims
&amp; Hers Health 股票的 “賣出” 評級。最後，TD Cowen 在 4 月 29 日的研究報告中將 Hims
&amp; Hers Health 的股票評級從 “買入” 下調至 “持有”，並將其股票目標價從 44.00 美元下調至 30.00 美元。兩位股票研究分析師給予該股 “買入” 評級，八位分析師給予 “持有” 評級，三位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “減持”，共識目標價為 38.92 美元。</p>
<ul>
<li>內部人士在與 NVIDIA 相關的 Navitas、Hims
&amp; Shift4 中交易數百萬</li>
</ul>
<p><strong>閲讀我們對 HIMS 的最新分析</strong></p>
<h2>Hims</h2>
<p>&amp; Hers Health 股票上漲 1.2%</p>
<p>該公司的債務與股本比率為 1.72，流動比率為 4.98，速動比率為 4.46。該公司的市值為 100.5 億美元，市盈率為 55.57，市盈增長比率為 2.93，貝塔值為 2.08。該公司的 50 日移動平均價格為 51.92 美元，200 日移動平均價格為 45.76 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 08/04 - 08/08</li>
</ul>
<p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近於 8 月 4 日星期一發布了季度財報。該公司報告本季度每股收益（EPS）為 0.17 美元，低於共識預期的 0.18 美元（差額為 0.01 美元）。該公司本季度的收入為 5.4483 億美元，而分析師預期為 5.5006 億美元。Hims
&amp; Hers Health 的股本回報率為 26.26%，淨利潤率為 9.63%。Hims
&amp; Hers Health 的收入同比增長 72.6%。在去年同期，該公司每股收益為 0.06 美元。Hims
&amp; Hers Health 已設定 2025 年第三季度的指引為每股收益。2025 財年的指引為每股收益。賣方分析師預計 Hims
&amp; Hers Health, Inc. 本年度將發佈 0.29 美元的每股收益。</p>
<h2>Hims</h2>
<p>&amp; Hers Health 的機構交易</p>
<p>一些對沖基金和其他機構投資者最近對該股票的持倉進行了調整。Marex Group plc 在第二季度購買了 Hims
&amp; Hers Health 的新股份，價值約為 53,626,000 美元。野村控股公司在第二季度將其在 Hims
&amp; Hers Health 的股份增加了 151.4%。野村控股公司現在擁有 161,052 股該公司的股票，價值 8,028,000 美元，此前在上一季度購買了額外的 96,997 股。Castleark Management LLC 在第二季度收購了 Hims
&amp; Hers Health 的新股份，價值約為 2,921,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Hims
&amp; Hers Health 的股份增加了 54.3%。Tower Research Capital LLC TRC 現在擁有 38,285 股該公司的股票，價值 1,909,000 美元，此前在上一季度購買了額外的 13,473 股。最後，SkyView Investment Advisors LLC 在第二季度收購了 Hims
&amp; Hers Health 的新股份，價值約為 226,000 美元。目前 63.52% 的股票由機構投資者持有。</p>
<h2>Hims</h2>
<p>&amp; Hers Health 公司簡介</p>
<p>(獲取免費報告)</p>
<p>Hims
&amp; Hers Health, Inc. 運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病學和初級保健的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票比 Hims
&amp; Hers Health 更好</li>
<li>為什麼股票行業對成功投資很重要？</li>
<li>小型股，大潛力：您應該瞭解的三家科技顛覆者</li>
<li>如何使用 MarketBeat 股票篩選器</li>
<li>在財報未達預期後，沃爾瑪仍然是頂級消費品投資選擇</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>思科如何為投資者構建新的增長故事</li>
</ul>
<p><em>此即時新聞提醒是通過敍述科學技術和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
<h2>您現在應該投資 1,000 美元在 Hims</h2>
<p>&amp; Hers Health 嗎？</p>
<p>在您考慮 Hims
&amp; Hers Health 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已確定五隻股票，頂級分析師正在悄悄地向客户推薦購買，以便在更廣泛的市場注意到之前... 而 Hims
&amp; Hers Health 並不在名單上。</p>
<p>儘管 Hims &amp; Hers Health 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

<p>Hims & Hers Health（紐約證券交易所代碼：HIMS）股價因首席執行官 Andrew Dudum 的內部出售而跳空下跌至 42.91 美元，他以每股 45.06 美元的價格出售了 128,127 股。該股收盤價為 44.71 美元，交易量接近 500 萬股。分析師已下調該股評級，Zacks 將其評級從 “強力買入” 調整為 “持有”。公司報告第二季度每股收益為 0.17 美元，未達到預期，營收為 5.4483 億美元，同比增長 72.6%。機構投資者持有該股 63.52% 的股份</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares gapped down prior to trading on Friday following insider selling activity. The stock had previously closed at $43.96, but opened at $42.91. Hims &amp; Hers Health shares last traded at $44.71, with a volume of 4,937,687 shares changing hands.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 的股票在週五交易前因內部人士賣出活動而出現跳空下跌。該股此前收於 43.96 美元，但開盤價為 42.91 美元。Hims
&amp; Hers Health 的股票最後交易價格為 44.71 美元，成交量為 4,937,687 股。</p>
</div><ul>
<li>Ozempic Boom: Hims &amp; Eli Lilly Lead Healthcare Bets</li>
</ul>
<div class="lb-trans"><ul>
<li>奧澤姆比熱潮：Hims
&amp; 艾利 Lilly 引領醫療保健投資</li>
</ul>
</div><p>Specifically, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $45.06, for a total value of $5,773,402.62. Following the completion of the sale, the chief executive officer directly owned 89,521 shares of the company's stock, valued at $4,033,816.26. The trade was a 58.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink.</p>
<div class="lb-trans"><p>具體來説，首席執行官安德魯·杜杜姆在 8 月 18 日星期一的交易中出售了 128,127 股公司的股票。這些股票以平均價格 45.06 美元出售，總價值為 5,773,402.62 美元。出售完成後，首席執行官直接持有公司 89,521 股股票，價值 4,033,816.26 美元。此次交易使其持股比例減少了 58.87%。該出售在與證券交易委員會的法律文件中披露，相關文件可通過此鏈接獲取。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>HIMS has been the subject of a number of research reports. Zacks Research cut shares of Hims &amp; Hers Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a report on Tuesday, August 5th. Deutsche Bank Aktiengesellschaft reaffirmed a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a report on Wednesday, May 7th. Citigroup reaffirmed a &#34;sell&#34; rating on shares of Hims &amp; Hers Health in a report on Monday, June 23rd. Finally, TD Cowen lowered shares of Hims &amp; Hers Health from a &#34;buy&#34; rating to a &#34;hold&#34; rating and dropped their price target for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of &#34;Reduce&#34; and a consensus target price of $38.92.</p>
<div class="lb-trans"><p>HIMS 已成為多份研究報告的主題。Zacks Research 在週二的報告中將 Hims
&amp; Hers Health 的股票評級從 “強力買入” 下調至 “持有”。Needham
&amp; Company LLC 在 8 月 5 日的報告中重申了對 Hims
&amp; Hers Health 股票的 “持有” 評級。德意志銀行在 5 月 7 日的報告中重申了對 Hims
&amp; Hers Health 股票的 “持有” 評級。花旗集團在 6 月 23 日的報告中重申了對 Hims
&amp; Hers Health 股票的 “賣出” 評級。最後，TD Cowen 在 4 月 29 日的研究報告中將 Hims
&amp; Hers Health 的股票評級從 “買入” 下調至 “持有”，並將其股票目標價從 44.00 美元下調至 30.00 美元。兩位股票研究分析師給予該股 “買入” 評級，八位分析師給予 “持有” 評級，三位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “減持”，共識目標價為 38.92 美元。</p>
</div><ul>
<li>Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, &amp; Shift4</li>
</ul>
<div class="lb-trans"><ul>
<li>內部人士在與 NVIDIA 相關的 Navitas、Hims
&amp; Shift4 中交易數百萬</li>
</ul>
</div><p><strong>Read Our Latest Analysis on HIMS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 HIMS 的最新分析</strong></p>
</div><h2>Hims &amp; Hers Health Stock Up 1.2%</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 股票上漲 1.2%</p>
</div><p>The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The firm has a market capitalization of $10.05 billion, a price-to-earnings ratio of 55.57, a price-to-earnings-growth ratio of 2.93 and a beta of 2.08. The firm's 50-day moving average price is $51.92 and its 200 day moving average price is $45.76.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 1.72，流動比率為 4.98，速動比率為 4.46。該公司的市值為 100.5 億美元，市盈率為 55.57，市盈增長比率為 2.93，貝塔值為 2.08。該公司的 50 日移動平均價格為 51.92 美元，200 日移動平均價格為 45.76 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 08/04 - 08/08</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 08/04 - 08/08</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims &amp; Hers Health had a return on equity of 26.26% and a net margin of 9.63%.Hims &amp; Hers Health's revenue was up 72.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.06 EPS. Hims &amp; Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts expect that Hims &amp; Hers Health, Inc. will post 0.29 EPS for the current year.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近於 8 月 4 日星期一發布了季度財報。該公司報告本季度每股收益（EPS）為 0.17 美元，低於共識預期的 0.18 美元（差額為 0.01 美元）。該公司本季度的收入為 5.4483 億美元，而分析師預期為 5.5006 億美元。Hims
&amp; Hers Health 的股本回報率為 26.26%，淨利潤率為 9.63%。Hims
&amp; Hers Health 的收入同比增長 72.6%。在去年同期，該公司每股收益為 0.06 美元。Hims
&amp; Hers Health 已設定 2025 年第三季度的指引為每股收益。2025 財年的指引為每股收益。賣方分析師預計 Hims
&amp; Hers Health, Inc. 本年度將發佈 0.29 美元的每股收益。</p>
</div><h2>Institutional Trading of Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 的機構交易</p>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Marex Group plc bought a new stake in shares of Hims &amp; Hers Health during the 2nd quarter worth about $53,626,000. Nomura Holdings Inc. grew its stake in shares of Hims &amp; Hers Health by 151.4% in the 2nd quarter. Nomura Holdings Inc. now owns 161,052 shares of the company's stock worth $8,028,000 after purchasing an additional 96,997 shares during the last quarter. Castleark Management LLC acquired a new position in shares of Hims &amp; Hers Health in the 2nd quarter worth approximately $2,921,000. Tower Research Capital LLC TRC grew its stake in shares of Hims &amp; Hers Health by 54.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 38,285 shares of the company's stock worth $1,909,000 after purchasing an additional 13,473 shares during the last quarter. Finally, SkyView Investment Advisors LLC acquired a new position in shares of Hims &amp; Hers Health in the 2nd quarter worth approximately $226,000. 63.52% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對該股票的持倉進行了調整。Marex Group plc 在第二季度購買了 Hims
&amp; Hers Health 的新股份，價值約為 53,626,000 美元。野村控股公司在第二季度將其在 Hims
&amp; Hers Health 的股份增加了 151.4%。野村控股公司現在擁有 161,052 股該公司的股票，價值 8,028,000 美元，此前在上一季度購買了額外的 96,997 股。Castleark Management LLC 在第二季度收購了 Hims
&amp; Hers Health 的新股份，價值約為 2,921,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Hims
&amp; Hers Health 的股份增加了 54.3%。Tower Research Capital LLC TRC 現在擁有 38,285 股該公司的股票，價值 1,909,000 美元，此前在上一季度購買了額外的 13,473 股。最後，SkyView Investment Advisors LLC 在第二季度收購了 Hims
&amp; Hers Health 的新股份，價值約為 226,000 美元。目前 63.52% 的股票由機構投資者持有。</p>
</div><h2>Hims &amp; Hers Health Company Profile</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 公司簡介</p>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. 運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病學和初級保健的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Small Cap, Big Potential: 3 Tech Disruptors You Should Know About</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>After Earnings Miss, Walmart Is Still a Top Consumer Staples Play</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>How Cisco Is Building a New Growth Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Hims
&amp; Hers Health 更好</li>
<li>為什麼股票行業對成功投資很重要？</li>
<li>小型股，大潛力：您應該瞭解的三家科技顛覆者</li>
<li>如何使用 MarketBeat 股票篩選器</li>
<li>在財報未達預期後，沃爾瑪仍然是頂級消費品投資選擇</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>思科如何為投資者構建新的增長故事</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒是通過敍述科學技術和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Hims</h2>
<p>&amp; Hers Health 嗎？</p>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Hims
&amp; Hers Health 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已確定五隻股票，頂級分析師正在悄悄地向客户推薦購買，以便在更廣泛的市場注意到之前... 而 Hims
&amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Hims &amp; Hers Health 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Hims & Hers Health（紐約證券交易所代碼：HIMS）的股票在內部人士拋售後出現跳空低開